Abstract
Level 1 evidence supports the role of cisplatin-based neoadjuvant chemotherapy for patients undergoing cystectomy for muscle-invasive transitional cell cancer of the bladder. However, the use of adjuvant chemotherapy remains attractive to many clinicians given that patients are often referred following cystectomy. To evaluate the effectiveness of adjuvant versus deferred cisplatin-based chemotherapy following cystectomy, European investigators conducted an intergroup, phase III, randomized, open-label study involving …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
